FAMR: A Four-Gene Prognostic Signature for Bladder Cancer with Single-Cell Validation

A 2026 study by Hui Yu analyzed 359 bladder cancer samples to develop a fatty acid metabolism-related prognostic signature. The dataset includes a four-gene FAM-RiskScore (FAMR) model comprising PATZ1, TTC6, AEBP1, and MAOA, validated with internal and external cohorts. It supports molecular subtyping and correlates with patient survival, immune infiltration, and in vitro functional assays.

Use Cases

• Predicting patient prognosis in bladder cancer based on the four-gene FAMR signature.
• Classifying bladder cancer into molecular subtypes (C1 and C2) based on fatty acid metabolism profiles.
• Investigating correlations between gene expression (e.g., AEBP1, MAOA) and immune infiltration scores.
• Validating the role of MAOA as a potential tumor suppressor via in vitro assay results referenced in the description.

Strengths

• Model validated using internal and external cohorts, as stated in the methods.
• Integrates single-cell RNA sequencing analysis to identify cell-type-specific gene expression.
• Includes results from in vitro proliferation and migration assays following MAOA knockdown.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (918.0 B), indicating limited raw data scope.

Provenance

Source

figshare, author Hui Yu

Collection Method

Analysis of 359 BLCA samples, with validation cohorts, functional enrichment, and single-cell RNA sequencing.

Freshness

Last updated 2026-03-18 07:35:20